{"gene":"CD40","run_date":"2026-06-09T22:57:17","timeline":{"discoveries":[{"year":1986,"finding":"CD40 (Bp50), a 50-kDa surface antigen expressed on all B cells, delivers positive signals that stimulate activated B cells to traverse the cell cycle; anti-Bp50 alone does not activate resting B cells but augments proliferation when combined with anti-Bp35 or anti-immunoglobulin, functioning similarly to B cell growth factor on activated but not resting B cells.","method":"Monoclonal antibody stimulation assays, B cell proliferation assays with purified resting vs. activated B cells, F(ab')2 fragment experiments","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct functional antibody stimulation assays with defined cell populations, replicated with multiple reagents, foundational paper establishing CD40 as a B cell activation co-signal","pmids":["3487090"],"is_preprint":false},{"year":1991,"finding":"CD40 receptor engagement on B-lineage cells (pro-B through activated mature B cells, but not resting mature B cells) stimulates tyrosine phosphorylation of four substrates (67, 72, 96, 113 kDa), induces rapid IP3 production (phosphoinositide turnover), and activates five distinct serine/threonine kinases; tyrosine kinase inhibitors (genistein, herbimycin A) blocked both tyrosine phosphorylation and downstream PI turnover and serine/threonine kinase activation.","method":"In vitro kinase assays, phosphoinositide turnover measurement, kinase inhibitor studies (H7, genistein, herbimycin A), immunoprecipitation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical assays with multiple orthogonal methods (kinase assays, PI turnover, pharmacological inhibitors), single lab but comprehensive mechanistic dissection","pmids":["1716631"],"is_preprint":false},{"year":1994,"finding":"CD40 is a 277-aa, 45–50 kDa type I transmembrane glycoprotein member of the TNFR superfamily; its gene maps to human chromosome 20q11-2–q13-2; it binds CD40-L (a ~35 kDa TNF superfamily member encoded on Xq24); cross-linking CD40 with immobilized anti-CD40 or CD40-L-expressing cells drives B cell proliferation, and in combination with IL-4 or IL-13 generates long-term B cell lines with IgE isotype switching.","method":"Recombinant protein studies, B cell stimulation assays, gene mapping, molecular characterization","journal":"Annual review of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — structural and functional characterization reviewed from multiple independent experimental studies establishing receptor identity and ligand binding","pmids":["7516669"],"is_preprint":false},{"year":1995,"finding":"Vascular endothelial cells express functional CD40; ligation of endothelial CD40 by soluble recombinant CD40 ligand (sgp39) activates endothelial cells, inducing E-selectin, ICAM-1, and augmenting VCAM-1 expression, leading to leukocyte adhesion; these effects are blocked by anti-gp39 mAb, anti-CD40 mAb, or soluble CD40.","method":"Soluble recombinant CD40L stimulation of endothelial cells, adhesion molecule expression assays, blocking antibody experiments, tissue immunostaining","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal blocking strategies (anti-ligand, anti-receptor, soluble receptor) with defined functional readout, replicated across conditions","pmids":["7540655"],"is_preprint":false},{"year":1996,"finding":"CD40-dependent T cell priming and activation occurs through CD40 signaling in antigen-presenting cells to upregulate B7.2 costimulatory molecules; reconstitution of CD40L-deficient mice with an activating anti-CD40 antibody (which increased B7.2 on spleen cells) restored both cytotoxic T cell and T cell-dependent B cell responses; these were abrogated by anti-B7 antibodies, placing B7-CD28 downstream of CD40 in T cell priming.","method":"CD40L-knockout mouse model, antibody reconstitution experiments, anti-B7 blockade, in vivo gene transfer model","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with knockouts, rescue experiment with activating antibody, and pathway blockade with anti-B7, multiple orthogonal approaches in single study","pmids":["8791591"],"is_preprint":false},{"year":1996,"finding":"TRAF5 is required for CD40-mediated B cell proliferation and upregulation of CD23, CD54, CD80, CD86, and Fas, as well as for CD40-stimulated IgE production with IL-4; TRAF5-deficient B cells show defects in these responses despite intact NF-κB and JNK activation by CD40, indicating TRAF5 mediates a distinct subset of CD40 signals.","method":"TRAF5 gene-targeted knockout mice, B cell proliferation assays, surface molecule expression analysis by flow cytometry, in vitro Ig production assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function (knockout) with multiple defined cellular phenotype readouts establishing TRAF5 as a specific downstream mediator","pmids":["10449775"],"is_preprint":false},{"year":2001,"finding":"CD40 signal transduction is initiated by receptor multimerization upon ligand binding; trimeric (but not monomeric) CD40 cytoplasmic domain activates NF-κB; the multimerized cytoplasmic domain forms complexes containing TRAF2, TRAF3, TRAF5, TRAF6, and c-IAP1; c-IAP1 association is indirect and depends on intact TRAF1/2/3 binding site.","method":"Defined multimeric constructs of CD40 cytoplasmic domain (soluble and myristoylated), NF-κB reporter assays in HEK293 cells, co-isolation and identification of signaling complexes, point mutations in TRAF binding sites","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with defined recombinant constructs, mutagenesis of binding sites, biochemical isolation of signaling complex, single lab but multiple orthogonal methods","pmids":["11562359"],"is_preprint":false},{"year":2003,"finding":"Tpl2 kinase is selectively required for CD40-mediated ERK activation in B cells and macrophages; Tpl2 is recruited to a CD40/TRAF6 complex upon CD40 stimulation; TRAF6 overexpression activates ERK in a Tpl2-dependent manner; loss of ERK (via Tpl2 knockout) impairs CD40-mediated IgE induction but not B cell proliferation, dissociating these two downstream outcomes.","method":"Tpl2 knockout mice, ERK/JNK/p38 activation assays, NF-κB activation assays, co-immunoprecipitation of CD40/TRAF6/Tpl2 complex, TRAF6 overexpression in Tpl2-/- cells, Ig production assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with multiple biochemical readouts, co-IP demonstrating complex formation, TRAF6 overexpression epistasis experiment, multiple orthogonal methods","pmids":["12881420"],"is_preprint":false},{"year":2004,"finding":"Act1, a novel adaptor molecule, negatively regulates CD40 and BAFFR signaling in B cells; Act1-deficient B cells show enhanced CD40-mediated survival with stronger IκB phosphorylation, NF-κB2 processing, and JNK/ERK/p38 activation; the autoimmune phenotype of Act1-deficient mice is blocked in CD40-Act1 double knockouts, placing Act1 as a negative regulator downstream of CD40.","method":"Act1 knockout mice, CD40-Act1 double knockout epistasis, B cell survival assays, IκB phosphorylation and NF-κB2 processing assays, MAPK activation assays","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic double knockout epistasis plus multiple biochemical signaling readouts establishing Act1 as a negative regulator of CD40 signaling","pmids":["15485634"],"is_preprint":false},{"year":2004,"finding":"CD40 signaling is absent in most germinal center (GC) B cells despite being required for pre- and post-GC stages; NF-κB transcription factors remain cytoplasmic in most GC B cells after CD40 stimulation, indicating lack of active CD40 signaling during GC expansion, with only a subset of centrocytes showing nuclear NF-κB.","method":"DNA microarray gene expression signature of CD40 signaling, NF-κB nuclear translocation analysis by immunostaining in lymphoid tissues, in vitro CD40 stimulation of transformed GC B cells","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gene expression signature validated by NF-κB localization in tissue sections, single lab with two orthogonal methods","pmids":["15331443"],"is_preprint":false},{"year":2001,"finding":"AKNA, an AT-hook transcription factor, directly binds the A/T-rich regulatory elements of both CD40 and CD40L promoters and coordinately regulates their expression; AKNA is a nuclear protein with PEST motifs expressed mainly in B and T lymphocytes and dendritic cells, predominantly in germinal center B cells.","method":"Promoter-binding assays, reporter gene assays, subcellular localization studies, expression analysis during B cell differentiation","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct promoter-binding demonstrated, functional reporter assays, subcellular localization with mechanistic consequence, single lab with multiple orthogonal methods","pmids":["11268217"],"is_preprint":false},{"year":2014,"finding":"NEDD4, an HECT-family E3 ubiquitin ligase, constitutively interacts with CD40 and mediates K63-linked ubiquitination of TRAF3; this TRAF3 ubiquitination is required for CD40-mediated AKT activation and modulates immunoglobulin class switching through regulation of activation-induced cytidine deaminase (AID) expression.","method":"Co-immunoprecipitation, ubiquitin chain-type analysis (K63-linkage), NEDD4 knockout/knockdown, AKT phosphorylation assays, AID expression analysis, class switch assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct biochemical identification of E3 ligase, ubiquitin chain type determined, functional consequence on AKT activation and class switching demonstrated, multiple orthogonal methods","pmids":["25072696"],"is_preprint":false},{"year":2018,"finding":"CD40-TRAF6 signaling in macrophages promotes atherosclerosis by driving CD40 and β2-integrin expression on classical monocytes, enhancing monocyte recruitment; small molecule TRAF-STOPs that selectively block CD40-TRAF6 (but not CD40-TRAF2/3/5) interactions reduce atherosclerosis and macrophage activation via reduced canonical NF-κB pathway phosphorylation, without impairing T cell proliferation, Ig isotype switching, or germinal center formation.","method":"TRAF-STOP small molecule inhibitors, Apoe-/- mouse atherosclerosis models, transcriptional profiling, NF-κB signaling assays, rHDL nanoparticle-targeted delivery, flow cytometry, in vitro macrophage migration/activation assays","journal":"Journal of the American College of Cardiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — selective inhibitor dissecting TRAF6-specific pathway, in vivo genetic and pharmacological validation, transcriptional profiling, multiple orthogonal methods","pmids":["29406859"],"is_preprint":false},{"year":2015,"finding":"Small molecule CD40-TRAF6 inhibitors identified by in silico docking block the physical interaction between CD40 cytoplasmic domain and TRAF6, reducing inflammation in peritonitis and sepsis mouse models without apparent side effects; this validates the CD40-TRAF6 protein-protein interaction as a tractable drug target.","method":"Computational docking, in vitro protein interaction assays, in vivo mouse models of peritonitis and sepsis","journal":"Journal of chemical information and modeling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in silico plus in vitro binding assay plus in vivo functional validation, single lab","pmids":["25622654"],"is_preprint":false},{"year":2022,"finding":"CD40 signaling in classical type 1 dendritic cells (cDC1s) induces expression of Cd70, Tnfsf9 (4-1BBL), Ptgs2 (COX-2), and Bcl2l1 (Bcl-xL); CD40-induced Bcl2l1 is required for cDC1 survival during anti-tumor CD8 T cell priming by maintaining mitochondrial membrane potential and preventing caspase activation in tumor-draining lymph nodes; re-expression of Bcl2l1 in Cd40-/- cDC1s reverses impaired antigen presentation.","method":"cDC1-specific CD40 knockout mice, Bcl2l1 re-expression rescue experiment, mitochondrial transmembrane potential assay, caspase activation assay, in vitro antigen presentation assays, tumor rejection models","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — cell-type-specific genetic knockout, molecular rescue by re-expression, mechanistic dissection with mitochondrial and caspase assays, in vivo and in vitro validation","pmids":["36271147"],"is_preprint":false},{"year":2002,"finding":"CD40 is expressed and functional on neuronal cells; CD40 ligation activates p44/42 MAPK in neurons, opposes JNK phosphorylation induced by NGF withdrawal, and protects neuronal cells from NGF- or serum withdrawal-induced injury; adult CD40-deficient mice show progressive neuronal dysfunction including reduced neurofilament isoforms, decreased Bcl-xL:Bax ratio, increased DNA fragmentation, and gross brain abnormality by 16 months.","method":"RT-PCR, western blot, immunofluorescence, MAPK activation assays, JNK assays, CD40 knockout mice, neuronal survival assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro signaling assays plus CD40 knockout mouse phenotype with multiple neuronal markers, replication across cell lines and primary neurons","pmids":["11847112"],"is_preprint":false},{"year":2006,"finding":"Soluble CD40L (sCD40L) binds directly to integrin α5β1 on monocytic U937 cells in a CD40- and αIIbβ3-independent manner; this binding induces translocation of α5β1 to Triton X-100-insoluble membrane fractions, activates ERK1/2 MAPK, and induces IL-8 gene expression; direct binding of sCD40L to purified α5β1 was confirmed in a solid-phase binding assay; sCD40L can simultaneously bind CD40 and α5β1 as they are independent binding interactions.","method":"Blocking antibody experiments, solid-phase binding assay with purified protein, lipid raft fractionation, ERK1/2 activation assays, IL-8 gene expression assays, α5β1-negative BJAB cell controls","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct binding with purified protein confirmed in solid-phase assay, multiple blocking experiments, functional downstream signaling measured, independent receptor controls","pmids":["17182621"],"is_preprint":false},{"year":2003,"finding":"CD40 ligation on endothelial cells induces expression of angiogenesis factors including VEGF, FGF-2, Flt-1, and Flt-4; in vivo injection of CD40L-expressing fibroblasts into human skin engrafted on SCID mice induces marked angiogenesis dependent on VEGF (blocked by anti-VEGF treatment), establishing CD40/CD40L as a VEGF-dependent proangiogenic pathway.","method":"Anti-CD40 antibody stimulation of cultured endothelial cells, SCID mouse human skin engraftment model, anti-VEGF blocking experiment, immunohistochemistry","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro and in vivo models with mechanistic blocking experiment (anti-VEGF), multiple angiogenic factors identified","pmids":["12874247"],"is_preprint":false},{"year":2003,"finding":"A20 overexpression in endothelial cells blocks CD40-induced NF-κB activation (upstream of IκBα degradation) and suppresses ICAM-1, VCAM-1, and E-selectin upregulation, but does not block CD40-induced tissue factor (TF) transcription, indicating CD40 induces TF through a non-NF-κB pathway; A20 also protects from CD40-mediated endothelial apoptosis.","method":"Transient transfection with CD40 and A20 expression constructs, NF-κB reporter assays, Western blot for IκBα, flow cytometry for adhesion molecules, colorimetric TF assay, RT-PCR, DNA content analysis for apoptosis","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 1 / Moderate — overexpression dissection with multiple molecular readouts distinguishing NF-κB-dependent vs. independent CD40 signaling branches, multiple orthogonal methods","pmids":["12885753"],"is_preprint":false},{"year":2006,"finding":"CD40 ligation on pancreatic islet beta-cells activates ERK1/2 and NF-κB signaling pathways, inducing secretion of IL-6, IL-8, MCP-1, and MIP-1β (a chemokine not previously known to be produced by islets) and upregulation of ICAM-1; ERK and NF-κB inhibitors suppress cytokine/chemokine production, establishing these pathways as the mechanism of CD40-driven islet inflammation.","method":"CD40L stimulation of human and nonhuman primate islets and NIT-1 insulinoma cells, ELISA, quantitative RT-PCR, double-immunofluorescence, ERK1/2 and NF-κB pathway inhibitors","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway inhibition with multiple molecular readouts, validated at both protein and mRNA levels, human and primate islets plus cell line","pmids":["16936191"],"is_preprint":false},{"year":2007,"finding":"CD40L-induced CD40L synthesis and MCP-1 release by endothelial cells is mediated through a redox-sensitive PI3K/Akt/NF-κB signaling axis; pharmacological inhibition of PI3K and p38 MAPK, and adenoviral inactivation of Akt and p38, blocked these effects; Akt overexpression augmented nuclear NF-κB translocation induced by CD40L, while Akt inactivation inhibited it.","method":"Pharmacological inhibitors (LY294002 for PI3K), adenoviral Akt and p38 overexpression/inactivation, confocal microscopy of NF-κB nuclear translocation, MCP-1 ELISA","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic (adenoviral) and pharmacological dissection of signaling pathway with NF-κB nuclear translocation as functional readout, multiple orthogonal methods","pmids":["17459878"],"is_preprint":false},{"year":1995,"finding":"CD40 ligation on B cells stimulates antigen processing; co-culture of B cells with CD40L-expressing insect cells or anti-CD40 mAb augments activation of antigen-specific T cell hybridomas at lower antigen doses; this effect is on an intracellular processing step (not peptide presentation directly), is independent of B7, LFA-1, or CD23 upregulation, and does not require B cell proliferation.","method":"T cell hybridoma activation assays, co-culture with CD40L-expressing insect cells, anti-CD40 mAb, peptide presentation controls, flow cytometry for surface molecules","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional T cell activation assays with multiple controls ruling out alternative mechanisms, single lab","pmids":["8566008"],"is_preprint":false},{"year":2008,"finding":"Neutrophils express CD40 (confirmed by RT-PCR and Western blot); platelet-neutrophil CD40-CD40L interaction enhances stimulation-induced platelet sCD40L release and augments neutrophil superoxide/ROS generation; this process is mediated via the PI3K/Akt pathway and forms a redox-controlled positive feedback loop where ROS further amplifies platelet sCD40L release.","method":"RT-PCR and Western blot for CD40 on neutrophils, ELISA for sCD40L, chemiluminescence and confocal microscopy for superoxide, flow cytometry for platelet-neutrophil conjugates, PI3K inhibitor (LY294002), N-acetylcysteine ROS scavenger, anti-CD40L blocking antibody","journal":"Thrombosis research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods confirming CD40 expression and functional pathway with pharmacological dissection, single lab","pmids":["18289643"],"is_preprint":false}],"current_model":"CD40 is a TNFR superfamily type I transmembrane receptor that lacks intrinsic kinase activity and signals by recruiting TRAF adaptor proteins (TRAF2, TRAF3, TRAF5, TRAF6, and c-IAP1) to its multimerized cytoplasmic domain upon CD40L (CD154) binding; downstream signaling activates NF-κB, MAPK pathways (ERK via Tpl2/TRAF6, JNK, p38), and PI3K/Akt, with distinct pathway branches controlling B cell proliferation, isotype switching, antigen processing, apoptosis resistance (via Bcl-xL), and inflammatory gene expression; NEDD4-mediated K63-ubiquitination of TRAF3 is required for AKT activation, Act1 negatively regulates the signaling complex, and AKNA coordinately transcribes both CD40 and CD40L; CD40 is expressed on B cells, dendritic cells, macrophages, endothelial cells, fibroblasts, neurons, eosinophils, and various other cell types where it mediates context-dependent functions including T cell priming through B7 upregulation, cDC1 survival via Bcl2l1, angiogenesis via VEGF induction, and inflammatory leukocyte recruitment."},"narrative":{"mechanistic_narrative":"CD40 is a type I transmembrane glycoprotein of the TNFR superfamily that functions as a co-stimulatory receptor coordinating adaptive and innate immune responses upon engagement by its ligand CD40L (CD154) [PMID:7516669]. First identified as the B cell surface antigen Bp50 that augments proliferation of activated B cells [PMID:3487090], CD40 lacks intrinsic kinase activity and signals through ligand-induced receptor multimerization: the trimerized cytoplasmic domain recruits a complex containing TRAF2, TRAF3, TRAF5, TRAF6, and c-IAP1 to drive NF-κB and downstream kinase activation [PMID:11562359]. Distinct TRAF branches partition CD40 outputs—TRAF6 recruits Tpl2 to selectively activate ERK and IgE induction without affecting B cell proliferation [PMID:12881420], TRAF5 mediates a separate subset of proliferative and surface-marker responses [PMID:10449775], and NEDD4-driven K63-ubiquitination of TRAF3 is required for AKT activation and immunoglobulin class switching via AID [PMID:25072696]. Signaling magnitude is restrained by the negative regulator Act1 [PMID:15485634], while the transcription factor AKNA coordinately activates both CD40 and CD40L promoters [PMID:11268217]. In the immune system, CD40 engagement on antigen-presenting cells upregulates B7.2 to license T cell priming [PMID:8791591], enhances B cell antigen processing [PMID:8566008], and in cDC1s induces Bcl-xL (Bcl2l1) to sustain dendritic cell survival during anti-tumor CD8 T cell priming [PMID:36271147]. Beyond lymphocytes, CD40 is functional on endothelial cells—where it induces adhesion molecules, leukocyte recruitment, and VEGF-dependent angiogenesis [PMID:7540655, PMID:12874247]—as well as on macrophages where CD40-TRAF6 signaling drives atherosclerotic monocyte recruitment [PMID:29406859], on neurons where it promotes survival via MAPK signaling [PMID:11847112], and on islet beta-cells and neutrophils that mount inflammatory responses through ERK/NF-κB and PI3K/Akt pathways [PMID:16936191, PMID:18289643].","teleology":[{"year":1986,"claim":"Established CD40 (Bp50) as a functional B cell surface molecule delivering activation co-signals, answering whether this antigen had a regulatory role rather than being a passive marker.","evidence":"Monoclonal antibody stimulation and proliferation assays on purified resting versus activated B cells","pmids":["3487090"],"confidence":"High","gaps":["Receptor identity and ligand unknown at this stage","No molecular signaling mechanism defined"]},{"year":1991,"claim":"Defined the immediate biochemical signaling response to CD40 engagement, showing it triggers tyrosine phosphorylation, phosphoinositide turnover, and serine/threonine kinase cascades.","evidence":"In vitro kinase assays, phosphoinositide turnover, and kinase inhibitor studies in B-lineage cells","pmids":["1716631"],"confidence":"High","gaps":["Specific kinases and adaptors not molecularly identified","Link to transcriptional output not established"]},{"year":1994,"claim":"Established CD40 as a TNFR-superfamily receptor for CD40L and linked CD40-IL-4/IL-13 co-stimulation to IgE isotype switching, defining its molecular identity and a functional output.","evidence":"Recombinant protein studies, gene mapping, and B cell stimulation/isotype switching assays (review of multiple studies)","pmids":["7516669"],"confidence":"High","gaps":["Cytoplasmic signaling adaptors not yet identified","Structural basis of receptor activation unresolved"]},{"year":1995,"claim":"Extended CD40 function beyond lymphocytes by showing endothelial CD40 drives adhesion molecule expression and leukocyte adhesion, and demonstrated CD40 augments B cell antigen processing independent of proliferation.","evidence":"Soluble CD40L stimulation with blocking antibodies on endothelium; T cell hybridoma activation assays with CD40L-expressing cells","pmids":["7540655","8566008"],"confidence":"High","gaps":["Intracellular signaling mediators in endothelium not defined","Antigen-processing step affected by CD40 not molecularly identified"]},{"year":1996,"claim":"Placed CD40 upstream of B7-CD28 co-stimulation in T cell priming and identified TRAF5 as a specific downstream mediator, beginning the dissection of branched CD40 outputs.","evidence":"CD40L-knockout mouse reconstitution with activating anti-CD40 plus anti-B7 blockade; TRAF5 knockout B cell phenotyping","pmids":["8791591","10449775"],"confidence":"High","gaps":["How TRAF5 selectively mediates a subset of signals while NF-κB/JNK remain intact unexplained","Other TRAF contributions not yet resolved"]},{"year":2001,"claim":"Defined the core activation mechanism—ligand-induced multimerization recruiting a TRAF2/3/5/6/c-IAP1 complex—and identified AKNA as a coordinate transcriptional regulator of CD40 and CD40L.","evidence":"Defined multimeric cytoplasmic-domain constructs with NF-κB reporters and complex co-isolation; promoter-binding and reporter assays for AKNA","pmids":["11562359","11268217"],"confidence":"High","gaps":["Stoichiometry and structure of the receptor-TRAF complex not resolved","How distinct TRAFs route to distinct outputs not fully defined"]},{"year":2002,"claim":"Demonstrated a non-immune role for CD40 in neuronal survival, showing CD40 signaling activates p44/42 MAPK and protects neurons, with CD40 loss causing progressive neuronal dysfunction.","evidence":"MAPK/JNK assays in neuronal cells plus CD40 knockout mouse brain phenotyping","pmids":["11847112"],"confidence":"High","gaps":["Ligand source for neuronal CD40 in vivo unclear","Adaptor usage in neurons not defined"]},{"year":2003,"claim":"Dissected endothelial CD40 signaling branches, establishing CD40-induced VEGF-dependent angiogenesis and an NF-κB-independent route to tissue factor, refining how CD40 outputs are pathway-partitioned.","evidence":"SCID mouse skin engraftment with anti-VEGF blockade; A20 overexpression dissecting NF-κB-dependent versus independent CD40 outputs","pmids":["12874247","12885753"],"confidence":"High","gaps":["The non-NF-κB pathway driving tissue factor not identified","Receptor-proximal events for angiogenic gene induction undefined"]},{"year":2003,"claim":"Identified Tpl2 as the kinase selectively coupling CD40-TRAF6 to ERK activation, dissociating ERK-dependent IgE induction from proliferation and providing a molecular basis for branched signaling.","evidence":"Tpl2 knockout mice, CD40/TRAF6/Tpl2 co-immunoprecipitation, and TRAF6 overexpression epistasis with Ig production assays","pmids":["12881420"],"confidence":"High","gaps":["How TRAF6 selectively engages Tpl2 versus other effectors unresolved","Contribution to other CD40 outputs not mapped"]},{"year":2004,"claim":"Established Act1 as a negative regulator restraining CD40 signaling and showed CD40 signaling is largely silent in germinal center B cells, revealing how CD40 output is gated in space and intensity.","evidence":"Act1 and CD40-Act1 double knockout epistasis with signaling readouts; CD40 gene-expression signature and NF-κB localization in lymphoid tissue","pmids":["15485634","15331443"],"confidence":"Medium","gaps":["Molecular mechanism by which Act1 dampens the complex not fully defined","What suppresses CD40 signaling within germinal centers unknown"]},{"year":2006,"claim":"Revealed CD40L can signal independently of CD40 by binding integrin α5β1, and extended CD40-driven inflammation to islet beta-cells via ERK/NF-κB chemokine induction.","evidence":"Solid-phase binding with purified α5β1 and downstream ERK/IL-8 assays; islet stimulation with ERK and NF-κB inhibitors","pmids":["17182621","16936191"],"confidence":"High","gaps":["Relative in vivo contribution of CD40 versus α5β1 ligation unclear","Receptor-proximal adaptors in islet beta-cells not defined"]},{"year":2007,"claim":"Defined a redox-sensitive PI3K/Akt/NF-κB axis amplifying CD40L signaling in endothelium and a platelet-neutrophil CD40-CD40L feedback loop, linking CD40 to thrombo-inflammatory amplification.","evidence":"Adenoviral Akt/p38 manipulation and PI3K inhibitors with NF-κB translocation readouts; neutrophil/platelet ROS and conjugate assays with PI3K inhibitor and ROS scavenger","pmids":["17459878","18289643"],"confidence":"Medium","gaps":["How PI3K/Akt couples to the receptor-TRAF complex in these cells not defined","In vivo relevance of the redox feedback loop not established"]},{"year":2014,"claim":"Identified NEDD4 as an E3 ligase that K63-ubiquitinates TRAF3 to enable CD40-driven AKT activation and class switching, connecting a specific ubiquitin event to a distinct signaling branch.","evidence":"Co-IP, K63-linkage ubiquitin analysis, NEDD4 loss-of-function, and AKT/AID/class-switch readouts","pmids":["25072696"],"confidence":"High","gaps":["Structural detail of NEDD4-CD40 interaction not resolved","How TRAF3 ubiquitination is integrated with other branches unclear"]},{"year":2015,"claim":"Validated the CD40-TRAF6 protein-protein interface as a druggable node by showing small-molecule inhibitors block binding and reduce inflammation in vivo.","evidence":"In silico docking, in vitro interaction assays, and peritonitis/sepsis mouse models","pmids":["25622654"],"confidence":"Medium","gaps":["Single-lab validation of specificity","Off-target effects not exhaustively excluded"]},{"year":2018,"claim":"Demonstrated selective CD40-TRAF6 blockade reduces atherosclerosis by limiting monocyte recruitment without impairing T cell or humoral immunity, establishing branch-selective therapeutic targeting.","evidence":"TRAF-STOP small molecules, Apoe-/- atherosclerosis models, transcriptional profiling, and NF-κB signaling assays","pmids":["29406859"],"confidence":"High","gaps":["Long-term safety of chronic CD40-TRAF6 inhibition unknown","Macrophage-intrinsic versus systemic contributions not fully separated"]},{"year":2022,"claim":"Showed CD40-induced Bcl-xL (Bcl2l1) sustains cDC1 survival to enable anti-tumor CD8 T cell priming, defining a survival output of CD40 in dendritic cells.","evidence":"cDC1-specific CD40 knockout, Bcl2l1 re-expression rescue, mitochondrial potential and caspase assays, and tumor rejection models","pmids":["36271147"],"confidence":"High","gaps":["Receptor-proximal events driving Bcl2l1 induction in cDC1 not mapped","Generalizability to other dendritic cell subsets unclear"]},{"year":null,"claim":"How distinct TRAF/adaptor configurations and post-translational modifications are integrated at the multimerized receptor to select cell-type-specific outputs remains incompletely resolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution structure of the assembled CD40-TRAF signaling complex in the corpus","Quantitative rules linking receptor occupancy to branch selection undefined","Mechanism of context-dependent output across cell types not unified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[2,6]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[16]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[6,7]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,2,3]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[6,7,11]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,5,14]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[12,13]}],"complexes":["CD40-TRAF signaling complex (TRAF2/TRAF3/TRAF5/TRAF6/c-IAP1)"],"partners":["CD40LG","TRAF2","TRAF3","TRAF5","TRAF6","NEDD4","ITGA5","TRAF1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P25942","full_name":"Tumor necrosis factor receptor superfamily member 5","aliases":["B-cell surface antigen CD40","Bp50","CD40L receptor","CDw40"],"length_aa":277,"mass_kda":30.6,"function":"Receptor for TNFSF5/CD40LG (PubMed:31331973). Transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglobulin secretion (By similarity)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P25942/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CD40","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CD40","total_profiled":1310},"omim":[{"mim_id":"619289","title":"ZINC FINGER PROTEIN 91, ATYPICAL E3 UBIQUITIN LIGASE; ZFP91","url":"https://www.omim.org/entry/619289"},{"mim_id":"619238","title":"IMMUNODEFICIENCY 79; IMD79","url":"https://www.omim.org/entry/619238"},{"mim_id":"619158","title":"PHOSPHATIDYLINOSITOL 3-KINASE-INTERACTING PROTEIN 1; PIK3IP1","url":"https://www.omim.org/entry/619158"},{"mim_id":"616005","title":"IMMUNODEFICIENCY 36 WITH LYMPHOPROLIFERATION; IMD36","url":"https://www.omim.org/entry/616005"},{"mim_id":"615772","title":"WAP FOUR-DISULFIDE CORE DOMAIN 21, PSEUDOGENE; WFDC21P","url":"https://www.omim.org/entry/615772"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":52.9}],"url":"https://www.proteinatlas.org/search/CD40"},"hgnc":{"alias_symbol":["p50","Bp50"],"prev_symbol":["TNFRSF5"]},"alphafold":{"accession":"P25942","domains":[{"cath_id":"2.10.50.10","chopping":"29-78","consensus_level":"medium","plddt":96.321,"start":29,"end":78},{"cath_id":"2.10.50.10","chopping":"122-213","consensus_level":"medium","plddt":92.5813,"start":122,"end":213}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P25942","model_url":"https://alphafold.ebi.ac.uk/files/AF-P25942-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P25942-F1-predicted_aligned_error_v6.png","plddt_mean":81.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CD40","jax_strain_url":"https://www.jax.org/strain/search?query=CD40"},"sequence":{"accession":"P25942","fasta_url":"https://rest.uniprot.org/uniprotkb/P25942.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P25942/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P25942"}},"corpus_meta":[{"pmid":"9597126","id":"PMC_9597126","title":"CD40 and CD154 in cell-mediated immunity.","date":"1998","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9597126","citation_count":1166,"is_preprint":false},{"pmid":"10647992","id":"PMC_10647992","title":"CD40-CD40 ligand.","date":"2000","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/10647992","citation_count":1131,"is_preprint":false},{"pmid":"7516669","id":"PMC_7516669","title":"The CD40 antigen and its ligand.","date":"1994","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7516669","citation_count":1094,"is_preprint":false},{"pmid":"11229815","id":"PMC_11229815","title":"The CD40/CD154 receptor/ligand dyad.","date":"2001","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/11229815","citation_count":610,"is_preprint":false},{"pmid":"15032580","id":"PMC_15032580","title":"CD40/CD154 interactions at the interface of tolerance and immunity.","date":"2004","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15032580","citation_count":522,"is_preprint":false},{"pmid":"8717526","id":"PMC_8717526","title":"Immune regulation by CD40 and its ligand GP39.","date":"1996","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8717526","citation_count":504,"is_preprint":false},{"pmid":"3487090","id":"PMC_3487090","title":"Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50.","date":"1986","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3487090","citation_count":496,"is_preprint":false},{"pmid":"11739273","id":"PMC_11739273","title":"CD40 signaling and plaque instability.","date":"2001","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/11739273","citation_count":483,"is_preprint":false},{"pmid":"31412220","id":"PMC_31412220","title":"CD40 Agonist Antibodies in Cancer Immunotherapy.","date":"2019","source":"Annual review of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31412220","citation_count":440,"is_preprint":false},{"pmid":"8637903","id":"PMC_8637903","title":"CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8637903","citation_count":409,"is_preprint":false},{"pmid":"7540655","id":"PMC_7540655","title":"Expression of functional CD40 by vascular endothelial cells.","date":"1995","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7540655","citation_count":362,"is_preprint":false},{"pmid":"23460534","id":"PMC_23460534","title":"Agonistic CD40 antibodies and cancer therapy.","date":"2013","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/23460534","citation_count":358,"is_preprint":false},{"pmid":"19524453","id":"PMC_19524453","title":"The role of CD40 and CD154/CD40L in dendritic cells.","date":"2009","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19524453","citation_count":348,"is_preprint":false},{"pmid":"8791591","id":"PMC_8791591","title":"CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40.","date":"1996","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8791591","citation_count":320,"is_preprint":false},{"pmid":"19679244","id":"PMC_19679244","title":"The CD40/CD40 ligand system: linking inflammation with atherothrombosis.","date":"2009","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/19679244","citation_count":303,"is_preprint":false},{"pmid":"3492534","id":"PMC_3492534","title":"Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40).","date":"1987","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/3492534","citation_count":175,"is_preprint":false},{"pmid":"29406859","id":"PMC_29406859","title":"Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis.","date":"2018","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/29406859","citation_count":165,"is_preprint":false},{"pmid":"10449775","id":"PMC_10449775","title":"Targeted disruption of Traf5 gene causes defects in CD40- and CD27-mediated lymphocyte activation.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10449775","citation_count":152,"is_preprint":false},{"pmid":"17317815","id":"PMC_17317815","title":"Prospect of targeting the CD40 pathway for cancer therapy.","date":"2007","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17317815","citation_count":150,"is_preprint":false},{"pmid":"17633023","id":"PMC_17633023","title":"TRAF proteins in CD40 signaling.","date":"2007","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/17633023","citation_count":147,"is_preprint":false},{"pmid":"11796241","id":"PMC_11796241","title":"CD40-CD40L interactions in atherosclerosis.","date":"2002","source":"Trends in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11796241","citation_count":147,"is_preprint":false},{"pmid":"1716631","id":"PMC_1716631","title":"Stimulation of protein tyrosine phosphorylation, phosphoinositide turnover, and multiple previously unidentified serine/threonine-specific protein kinases by the Pan-B-cell receptor CD40/Bp50 at discrete developmental stages of human B-cell ontogeny.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1716631","citation_count":147,"is_preprint":false},{"pmid":"7554483","id":"PMC_7554483","title":"CD40 expression by human fibroblasts.","date":"1995","source":"Clinical immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/7554483","citation_count":146,"is_preprint":false},{"pmid":"15331443","id":"PMC_15331443","title":"Tracking CD40 signaling during germinal center development.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15331443","citation_count":145,"is_preprint":false},{"pmid":"12489023","id":"PMC_12489023","title":"Prospects for CD40-directed experimental therapy of human cancer.","date":"2003","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/12489023","citation_count":143,"is_preprint":false},{"pmid":"8809473","id":"PMC_8809473","title":"Functions of CD40 and its ligand, gp39 (CD40L).","date":"1996","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8809473","citation_count":139,"is_preprint":false},{"pmid":"19904719","id":"PMC_19904719","title":"CD40/CD40L signaling and its implication in health and disease.","date":"2009","source":"BioFactors (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19904719","citation_count":134,"is_preprint":false},{"pmid":"12881420","id":"PMC_12881420","title":"Tpl2 transduces CD40 and TNF signals that activate ERK and regulates IgE induction by CD40.","date":"2003","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12881420","citation_count":133,"is_preprint":false},{"pmid":"23414607","id":"PMC_23414607","title":"The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.","date":"2013","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23414607","citation_count":132,"is_preprint":false},{"pmid":"9368772","id":"PMC_9368772","title":"The CD40 pathway in allograft rejection, acceptance, and tolerance.","date":"1997","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9368772","citation_count":125,"is_preprint":false},{"pmid":"8647193","id":"PMC_8647193","title":"Human dendritic cells activate T lymphocytes via a CD40: CD40 ligand-dependent pathway.","date":"1996","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8647193","citation_count":122,"is_preprint":false},{"pmid":"18977174","id":"PMC_18977174","title":"CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease.","date":"2008","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18977174","citation_count":119,"is_preprint":false},{"pmid":"15485634","id":"PMC_15485634","title":"Act1, a negative regulator in CD40- and BAFF-mediated B cell survival.","date":"2004","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/15485634","citation_count":115,"is_preprint":false},{"pmid":"12906261","id":"PMC_12906261","title":"CD40 and dendritic cell function.","date":"2003","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12906261","citation_count":114,"is_preprint":false},{"pmid":"19652870","id":"PMC_19652870","title":"The multi-functionality of CD40L and its receptor CD40 in atherosclerosis.","date":"2009","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/19652870","citation_count":114,"is_preprint":false},{"pmid":"21244217","id":"PMC_21244217","title":"The CD40-CD40L system in cardiovascular disease.","date":"2011","source":"Annals of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21244217","citation_count":112,"is_preprint":false},{"pmid":"8601642","id":"PMC_8601642","title":"CD40 expression by human peripheral blood eosinophils.","date":"1996","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/8601642","citation_count":105,"is_preprint":false},{"pmid":"15795333","id":"PMC_15795333","title":"CD40/CD40 ligand signaling in mouse cerebral microvasculature after focal ischemia/reperfusion.","date":"2005","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/15795333","citation_count":105,"is_preprint":false},{"pmid":"10741409","id":"PMC_10741409","title":"Chemokines and CD40 expression in human fibroblasts.","date":"2000","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10741409","citation_count":104,"is_preprint":false},{"pmid":"17482093","id":"PMC_17482093","title":"CD40 and its ligand in atherosclerosis.","date":"2007","source":"Trends in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17482093","citation_count":103,"is_preprint":false},{"pmid":"11847112","id":"PMC_11847112","title":"CD40 is expressed and functional on neuronal cells.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11847112","citation_count":101,"is_preprint":false},{"pmid":"15078798","id":"PMC_15078798","title":"Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers.","date":"2004","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/15078798","citation_count":96,"is_preprint":false},{"pmid":"9422418","id":"PMC_9422418","title":"CD40 and CD40 ligand (CD154) are coexpressed on microvessels in vivo in human cardiac allograft rejection.","date":"1997","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/9422418","citation_count":95,"is_preprint":false},{"pmid":"23589109","id":"PMC_23589109","title":"CD40 immunotherapy for pancreatic cancer.","date":"2013","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/23589109","citation_count":93,"is_preprint":false},{"pmid":"10856699","id":"PMC_10856699","title":"CD154 (CD40 ligand).","date":"2000","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10856699","citation_count":92,"is_preprint":false},{"pmid":"29773027","id":"PMC_29773027","title":"Functions of CD40 and Its Ligand, gp39 (CD40L).","date":"2017","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29773027","citation_count":90,"is_preprint":false},{"pmid":"11594459","id":"PMC_11594459","title":"Signaling by CD40 and its mimics in B cell activation.","date":"2001","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/11594459","citation_count":90,"is_preprint":false},{"pmid":"33804039","id":"PMC_33804039","title":"Agonistic CD40 Antibodies in Cancer Treatment.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33804039","citation_count":87,"is_preprint":false},{"pmid":"17182621","id":"PMC_17182621","title":"CD40 ligand binds to alpha5beta1 integrin and triggers cell signaling.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17182621","citation_count":87,"is_preprint":false},{"pmid":"15952932","id":"PMC_15952932","title":"Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease.","date":"2005","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15952932","citation_count":86,"is_preprint":false},{"pmid":"9250584","id":"PMC_9250584","title":"Functional role of CD40 and its ligand.","date":"1997","source":"International archives of allergy and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9250584","citation_count":85,"is_preprint":false},{"pmid":"3500063","id":"PMC_3500063","title":"Synergistic interaction between interleukin 4 and anti-Bp50 (CDw40) revealed in a novel B cell restimulation assay.","date":"1987","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/3500063","citation_count":84,"is_preprint":false},{"pmid":"18043876","id":"PMC_18043876","title":"CD40/CD40L system and vascular disease.","date":"2007","source":"Internal and emergency medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18043876","citation_count":77,"is_preprint":false},{"pmid":"11268217","id":"PMC_11268217","title":"Regulation of CD40 and CD40 ligand by the AT-hook transcription factor AKNA.","date":"2001","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/11268217","citation_count":73,"is_preprint":false},{"pmid":"17459878","id":"PMC_17459878","title":"CD40-40L signaling in vascular inflammation.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17459878","citation_count":72,"is_preprint":false},{"pmid":"12209589","id":"PMC_12209589","title":"Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10.","date":"2002","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12209589","citation_count":71,"is_preprint":false},{"pmid":"12509450","id":"PMC_12509450","title":"Delineation of a novel pathway that regulates CD154 (CD40 ligand) expression.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12509450","citation_count":71,"is_preprint":false},{"pmid":"21529993","id":"PMC_21529993","title":"CD40 ligand: a neo-inflammatory molecule in vascular diseases.","date":"2011","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/21529993","citation_count":70,"is_preprint":false},{"pmid":"21928689","id":"PMC_21928689","title":"CD40/CD40 ligand interactions in immune responses and pulmonary immunity.","date":"2011","source":"Nagoya journal of medical science","url":"https://pubmed.ncbi.nlm.nih.gov/21928689","citation_count":68,"is_preprint":false},{"pmid":"2965643","id":"PMC_2965643","title":"Soluble CD23 is released by B lymphocytes cycling in response to interleukin 4 and anti-Bp50 (CDw40).","date":"1988","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/2965643","citation_count":68,"is_preprint":false},{"pmid":"11163401","id":"PMC_11163401","title":"Role for CD40-CD40 ligand interactions in the immune response to solid tumours.","date":"2000","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11163401","citation_count":67,"is_preprint":false},{"pmid":"12885753","id":"PMC_12885753","title":"A20 protects from CD40-CD40 ligand-mediated endothelial cell activation and apoptosis.","date":"2003","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/12885753","citation_count":64,"is_preprint":false},{"pmid":"9144474","id":"PMC_9144474","title":"Bidirectional regulation of human B cell responses by CD40-CD40 ligand interactions.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9144474","citation_count":63,"is_preprint":false},{"pmid":"11810060","id":"PMC_11810060","title":"The CD154-CD40 costimulatory pathway in transplantation.","date":"2002","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/11810060","citation_count":62,"is_preprint":false},{"pmid":"18289643","id":"PMC_18289643","title":"Neutrophil CD40 enhances platelet-mediated inflammation.","date":"2008","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/18289643","citation_count":61,"is_preprint":false},{"pmid":"12874247","id":"PMC_12874247","title":"Proangiogenic function of CD40 ligand-CD40 interactions.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12874247","citation_count":61,"is_preprint":false},{"pmid":"36271147","id":"PMC_36271147","title":"Mechanisms of CD40-dependent cDC1 licensing beyond costimulation.","date":"2022","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36271147","citation_count":57,"is_preprint":false},{"pmid":"25622654","id":"PMC_25622654","title":"Discovery of small molecule CD40-TRAF6 inhibitors.","date":"2015","source":"Journal of chemical information and modeling","url":"https://pubmed.ncbi.nlm.nih.gov/25622654","citation_count":57,"is_preprint":false},{"pmid":"7507684","id":"PMC_7507684","title":"Role of CD40-CD40-ligand interaction in Ig-isotype switching.","date":"1993","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7507684","citation_count":57,"is_preprint":false},{"pmid":"7564113","id":"PMC_7564113","title":"Inhibition of the CD40-CD40ligand pathway prevents murine membranous glomerulonephritis.","date":"1995","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/7564113","citation_count":57,"is_preprint":false},{"pmid":"10398138","id":"PMC_10398138","title":"CD40 expression in bladder cancer.","date":"1999","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10398138","citation_count":57,"is_preprint":false},{"pmid":"31403344","id":"PMC_31403344","title":"Concepts for agonistic targeting of CD40 in immuno-oncology.","date":"2019","source":"Human vaccines & immunotherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/31403344","citation_count":56,"is_preprint":false},{"pmid":"16936191","id":"PMC_16936191","title":"CD40-CD40 ligand interaction activates proinflammatory pathways in pancreatic islets.","date":"2006","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/16936191","citation_count":55,"is_preprint":false},{"pmid":"11485931","id":"PMC_11485931","title":"Role of CD40-CVD40L in mouse severe malaria.","date":"2001","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11485931","citation_count":54,"is_preprint":false},{"pmid":"26268734","id":"PMC_26268734","title":"Update on CD40 and CD154 blockade in transplant models.","date":"2015","source":"Immunotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/26268734","citation_count":52,"is_preprint":false},{"pmid":"19647448","id":"PMC_19647448","title":"The Janus faces of CD40 in cancer.","date":"2009","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19647448","citation_count":52,"is_preprint":false},{"pmid":"15230296","id":"PMC_15230296","title":"The role of CD40 ligand in systemic lupus erythematosus.","date":"2004","source":"Lupus","url":"https://pubmed.ncbi.nlm.nih.gov/15230296","citation_count":52,"is_preprint":false},{"pmid":"10985254","id":"PMC_10985254","title":"The emerging role of CD40 ligand in HIV infection.","date":"2000","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/10985254","citation_count":51,"is_preprint":false},{"pmid":"35456932","id":"PMC_35456932","title":"CD40-CD40L in Neurological Disease.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35456932","citation_count":50,"is_preprint":false},{"pmid":"11604589","id":"PMC_11604589","title":"Regulation of CD40 ligand expression in systemic lupus erythematosus.","date":"2001","source":"Current opinion in rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/11604589","citation_count":50,"is_preprint":false},{"pmid":"17324402","id":"PMC_17324402","title":"CD40-CD40 ligand mediates the recruitment of leukocytes and platelets in the inflamed murine colon.","date":"2006","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/17324402","citation_count":49,"is_preprint":false},{"pmid":"27731400","id":"PMC_27731400","title":"miRNA-145 inhibits VSMC proliferation by targeting CD40.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27731400","citation_count":49,"is_preprint":false},{"pmid":"15367912","id":"PMC_15367912","title":"CD40 ligand gene and Kawasaki disease.","date":"2004","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/15367912","citation_count":47,"is_preprint":false},{"pmid":"18495129","id":"PMC_18495129","title":"Anthocyanin attenuates CD40-mediated endothelial cell activation and apoptosis by inhibiting CD40-induced MAPK activation.","date":"2008","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/18495129","citation_count":47,"is_preprint":false},{"pmid":"7865800","id":"PMC_7865800","title":"Regulation of CD40 ligand expression and use of recombinant CD40 ligand for studying B cell growth and differentiation.","date":"1994","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7865800","citation_count":47,"is_preprint":false},{"pmid":"9792321","id":"PMC_9792321","title":"Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells.","date":"1998","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/9792321","citation_count":46,"is_preprint":false},{"pmid":"9041191","id":"PMC_9041191","title":"Endothelial expression of CD40 in renal cell carcinoma.","date":"1997","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9041191","citation_count":46,"is_preprint":false},{"pmid":"25072696","id":"PMC_25072696","title":"NEDD4 ubiquitinates TRAF3 to promote CD40-mediated AKT activation.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25072696","citation_count":46,"is_preprint":false},{"pmid":"10569134","id":"PMC_10569134","title":"CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders.","date":"1999","source":"The International journal of biological markers","url":"https://pubmed.ncbi.nlm.nih.gov/10569134","citation_count":45,"is_preprint":false},{"pmid":"12510151","id":"PMC_12510151","title":"Differential regulation of cell survival by CD40.","date":"2003","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/12510151","citation_count":44,"is_preprint":false},{"pmid":"10634610","id":"PMC_10634610","title":"Expression of CD40 and CD40 ligand in the human conjunctival epithelium.","date":"2000","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/10634610","citation_count":44,"is_preprint":false},{"pmid":"18287517","id":"PMC_18287517","title":"A functional TNFRSF5 gene variant is associated with risk of lymphoma.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18287517","citation_count":43,"is_preprint":false},{"pmid":"11056083","id":"PMC_11056083","title":"Immune regulation by CD40-CD40-l interactions - 2; Y2K update.","date":"2000","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/11056083","citation_count":42,"is_preprint":false},{"pmid":"11562359","id":"PMC_11562359","title":"Molecular characterization of CD40 signaling intermediates.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11562359","citation_count":41,"is_preprint":false},{"pmid":"11042507","id":"PMC_11042507","title":"CD40 ligand in CLL pathogenesis and therapy.","date":"2000","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/11042507","citation_count":39,"is_preprint":false},{"pmid":"17823201","id":"PMC_17823201","title":"Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse.","date":"2007","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/17823201","citation_count":38,"is_preprint":false},{"pmid":"38102001","id":"PMC_38102001","title":"Harnessing the potential of CD40 agonism in cancer therapy.","date":"2023","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/38102001","citation_count":37,"is_preprint":false},{"pmid":"8566008","id":"PMC_8566008","title":"CD40-CD40 ligand interactions stimulate B cell antigen processing.","date":"1995","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8566008","citation_count":37,"is_preprint":false},{"pmid":"11212229","id":"PMC_11212229","title":"Coexpression of CD40 and CD40 ligand in cutaneous T-cell lymphoma (mycosis fungoides).","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11212229","citation_count":36,"is_preprint":false},{"pmid":"21074067","id":"PMC_21074067","title":"Biology and clinical applications of CD40 in cancer treatment.","date":"2010","source":"Seminars in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21074067","citation_count":36,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":42181,"output_tokens":6701,"usd":0.113529,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15777,"output_tokens":5260,"usd":0.105192,"stage2_stop_reason":"end_turn"},"total_usd":0.218721,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1986,\n      \"finding\": \"CD40 (Bp50), a 50-kDa surface antigen expressed on all B cells, delivers positive signals that stimulate activated B cells to traverse the cell cycle; anti-Bp50 alone does not activate resting B cells but augments proliferation when combined with anti-Bp35 or anti-immunoglobulin, functioning similarly to B cell growth factor on activated but not resting B cells.\",\n      \"method\": \"Monoclonal antibody stimulation assays, B cell proliferation assays with purified resting vs. activated B cells, F(ab')2 fragment experiments\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct functional antibody stimulation assays with defined cell populations, replicated with multiple reagents, foundational paper establishing CD40 as a B cell activation co-signal\",\n      \"pmids\": [\"3487090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"CD40 receptor engagement on B-lineage cells (pro-B through activated mature B cells, but not resting mature B cells) stimulates tyrosine phosphorylation of four substrates (67, 72, 96, 113 kDa), induces rapid IP3 production (phosphoinositide turnover), and activates five distinct serine/threonine kinases; tyrosine kinase inhibitors (genistein, herbimycin A) blocked both tyrosine phosphorylation and downstream PI turnover and serine/threonine kinase activation.\",\n      \"method\": \"In vitro kinase assays, phosphoinositide turnover measurement, kinase inhibitor studies (H7, genistein, herbimycin A), immunoprecipitation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical assays with multiple orthogonal methods (kinase assays, PI turnover, pharmacological inhibitors), single lab but comprehensive mechanistic dissection\",\n      \"pmids\": [\"1716631\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"CD40 is a 277-aa, 45–50 kDa type I transmembrane glycoprotein member of the TNFR superfamily; its gene maps to human chromosome 20q11-2–q13-2; it binds CD40-L (a ~35 kDa TNF superfamily member encoded on Xq24); cross-linking CD40 with immobilized anti-CD40 or CD40-L-expressing cells drives B cell proliferation, and in combination with IL-4 or IL-13 generates long-term B cell lines with IgE isotype switching.\",\n      \"method\": \"Recombinant protein studies, B cell stimulation assays, gene mapping, molecular characterization\",\n      \"journal\": \"Annual review of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — structural and functional characterization reviewed from multiple independent experimental studies establishing receptor identity and ligand binding\",\n      \"pmids\": [\"7516669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Vascular endothelial cells express functional CD40; ligation of endothelial CD40 by soluble recombinant CD40 ligand (sgp39) activates endothelial cells, inducing E-selectin, ICAM-1, and augmenting VCAM-1 expression, leading to leukocyte adhesion; these effects are blocked by anti-gp39 mAb, anti-CD40 mAb, or soluble CD40.\",\n      \"method\": \"Soluble recombinant CD40L stimulation of endothelial cells, adhesion molecule expression assays, blocking antibody experiments, tissue immunostaining\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal blocking strategies (anti-ligand, anti-receptor, soluble receptor) with defined functional readout, replicated across conditions\",\n      \"pmids\": [\"7540655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"CD40-dependent T cell priming and activation occurs through CD40 signaling in antigen-presenting cells to upregulate B7.2 costimulatory molecules; reconstitution of CD40L-deficient mice with an activating anti-CD40 antibody (which increased B7.2 on spleen cells) restored both cytotoxic T cell and T cell-dependent B cell responses; these were abrogated by anti-B7 antibodies, placing B7-CD28 downstream of CD40 in T cell priming.\",\n      \"method\": \"CD40L-knockout mouse model, antibody reconstitution experiments, anti-B7 blockade, in vivo gene transfer model\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with knockouts, rescue experiment with activating antibody, and pathway blockade with anti-B7, multiple orthogonal approaches in single study\",\n      \"pmids\": [\"8791591\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"TRAF5 is required for CD40-mediated B cell proliferation and upregulation of CD23, CD54, CD80, CD86, and Fas, as well as for CD40-stimulated IgE production with IL-4; TRAF5-deficient B cells show defects in these responses despite intact NF-κB and JNK activation by CD40, indicating TRAF5 mediates a distinct subset of CD40 signals.\",\n      \"method\": \"TRAF5 gene-targeted knockout mice, B cell proliferation assays, surface molecule expression analysis by flow cytometry, in vitro Ig production assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function (knockout) with multiple defined cellular phenotype readouts establishing TRAF5 as a specific downstream mediator\",\n      \"pmids\": [\"10449775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CD40 signal transduction is initiated by receptor multimerization upon ligand binding; trimeric (but not monomeric) CD40 cytoplasmic domain activates NF-κB; the multimerized cytoplasmic domain forms complexes containing TRAF2, TRAF3, TRAF5, TRAF6, and c-IAP1; c-IAP1 association is indirect and depends on intact TRAF1/2/3 binding site.\",\n      \"method\": \"Defined multimeric constructs of CD40 cytoplasmic domain (soluble and myristoylated), NF-κB reporter assays in HEK293 cells, co-isolation and identification of signaling complexes, point mutations in TRAF binding sites\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with defined recombinant constructs, mutagenesis of binding sites, biochemical isolation of signaling complex, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"11562359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Tpl2 kinase is selectively required for CD40-mediated ERK activation in B cells and macrophages; Tpl2 is recruited to a CD40/TRAF6 complex upon CD40 stimulation; TRAF6 overexpression activates ERK in a Tpl2-dependent manner; loss of ERK (via Tpl2 knockout) impairs CD40-mediated IgE induction but not B cell proliferation, dissociating these two downstream outcomes.\",\n      \"method\": \"Tpl2 knockout mice, ERK/JNK/p38 activation assays, NF-κB activation assays, co-immunoprecipitation of CD40/TRAF6/Tpl2 complex, TRAF6 overexpression in Tpl2-/- cells, Ig production assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with multiple biochemical readouts, co-IP demonstrating complex formation, TRAF6 overexpression epistasis experiment, multiple orthogonal methods\",\n      \"pmids\": [\"12881420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Act1, a novel adaptor molecule, negatively regulates CD40 and BAFFR signaling in B cells; Act1-deficient B cells show enhanced CD40-mediated survival with stronger IκB phosphorylation, NF-κB2 processing, and JNK/ERK/p38 activation; the autoimmune phenotype of Act1-deficient mice is blocked in CD40-Act1 double knockouts, placing Act1 as a negative regulator downstream of CD40.\",\n      \"method\": \"Act1 knockout mice, CD40-Act1 double knockout epistasis, B cell survival assays, IκB phosphorylation and NF-κB2 processing assays, MAPK activation assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic double knockout epistasis plus multiple biochemical signaling readouts establishing Act1 as a negative regulator of CD40 signaling\",\n      \"pmids\": [\"15485634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CD40 signaling is absent in most germinal center (GC) B cells despite being required for pre- and post-GC stages; NF-κB transcription factors remain cytoplasmic in most GC B cells after CD40 stimulation, indicating lack of active CD40 signaling during GC expansion, with only a subset of centrocytes showing nuclear NF-κB.\",\n      \"method\": \"DNA microarray gene expression signature of CD40 signaling, NF-κB nuclear translocation analysis by immunostaining in lymphoid tissues, in vitro CD40 stimulation of transformed GC B cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gene expression signature validated by NF-κB localization in tissue sections, single lab with two orthogonal methods\",\n      \"pmids\": [\"15331443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"AKNA, an AT-hook transcription factor, directly binds the A/T-rich regulatory elements of both CD40 and CD40L promoters and coordinately regulates their expression; AKNA is a nuclear protein with PEST motifs expressed mainly in B and T lymphocytes and dendritic cells, predominantly in germinal center B cells.\",\n      \"method\": \"Promoter-binding assays, reporter gene assays, subcellular localization studies, expression analysis during B cell differentiation\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct promoter-binding demonstrated, functional reporter assays, subcellular localization with mechanistic consequence, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"11268217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NEDD4, an HECT-family E3 ubiquitin ligase, constitutively interacts with CD40 and mediates K63-linked ubiquitination of TRAF3; this TRAF3 ubiquitination is required for CD40-mediated AKT activation and modulates immunoglobulin class switching through regulation of activation-induced cytidine deaminase (AID) expression.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitin chain-type analysis (K63-linkage), NEDD4 knockout/knockdown, AKT phosphorylation assays, AID expression analysis, class switch assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct biochemical identification of E3 ligase, ubiquitin chain type determined, functional consequence on AKT activation and class switching demonstrated, multiple orthogonal methods\",\n      \"pmids\": [\"25072696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CD40-TRAF6 signaling in macrophages promotes atherosclerosis by driving CD40 and β2-integrin expression on classical monocytes, enhancing monocyte recruitment; small molecule TRAF-STOPs that selectively block CD40-TRAF6 (but not CD40-TRAF2/3/5) interactions reduce atherosclerosis and macrophage activation via reduced canonical NF-κB pathway phosphorylation, without impairing T cell proliferation, Ig isotype switching, or germinal center formation.\",\n      \"method\": \"TRAF-STOP small molecule inhibitors, Apoe-/- mouse atherosclerosis models, transcriptional profiling, NF-κB signaling assays, rHDL nanoparticle-targeted delivery, flow cytometry, in vitro macrophage migration/activation assays\",\n      \"journal\": \"Journal of the American College of Cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — selective inhibitor dissecting TRAF6-specific pathway, in vivo genetic and pharmacological validation, transcriptional profiling, multiple orthogonal methods\",\n      \"pmids\": [\"29406859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Small molecule CD40-TRAF6 inhibitors identified by in silico docking block the physical interaction between CD40 cytoplasmic domain and TRAF6, reducing inflammation in peritonitis and sepsis mouse models without apparent side effects; this validates the CD40-TRAF6 protein-protein interaction as a tractable drug target.\",\n      \"method\": \"Computational docking, in vitro protein interaction assays, in vivo mouse models of peritonitis and sepsis\",\n      \"journal\": \"Journal of chemical information and modeling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in silico plus in vitro binding assay plus in vivo functional validation, single lab\",\n      \"pmids\": [\"25622654\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CD40 signaling in classical type 1 dendritic cells (cDC1s) induces expression of Cd70, Tnfsf9 (4-1BBL), Ptgs2 (COX-2), and Bcl2l1 (Bcl-xL); CD40-induced Bcl2l1 is required for cDC1 survival during anti-tumor CD8 T cell priming by maintaining mitochondrial membrane potential and preventing caspase activation in tumor-draining lymph nodes; re-expression of Bcl2l1 in Cd40-/- cDC1s reverses impaired antigen presentation.\",\n      \"method\": \"cDC1-specific CD40 knockout mice, Bcl2l1 re-expression rescue experiment, mitochondrial transmembrane potential assay, caspase activation assay, in vitro antigen presentation assays, tumor rejection models\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cell-type-specific genetic knockout, molecular rescue by re-expression, mechanistic dissection with mitochondrial and caspase assays, in vivo and in vitro validation\",\n      \"pmids\": [\"36271147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CD40 is expressed and functional on neuronal cells; CD40 ligation activates p44/42 MAPK in neurons, opposes JNK phosphorylation induced by NGF withdrawal, and protects neuronal cells from NGF- or serum withdrawal-induced injury; adult CD40-deficient mice show progressive neuronal dysfunction including reduced neurofilament isoforms, decreased Bcl-xL:Bax ratio, increased DNA fragmentation, and gross brain abnormality by 16 months.\",\n      \"method\": \"RT-PCR, western blot, immunofluorescence, MAPK activation assays, JNK assays, CD40 knockout mice, neuronal survival assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro signaling assays plus CD40 knockout mouse phenotype with multiple neuronal markers, replication across cell lines and primary neurons\",\n      \"pmids\": [\"11847112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Soluble CD40L (sCD40L) binds directly to integrin α5β1 on monocytic U937 cells in a CD40- and αIIbβ3-independent manner; this binding induces translocation of α5β1 to Triton X-100-insoluble membrane fractions, activates ERK1/2 MAPK, and induces IL-8 gene expression; direct binding of sCD40L to purified α5β1 was confirmed in a solid-phase binding assay; sCD40L can simultaneously bind CD40 and α5β1 as they are independent binding interactions.\",\n      \"method\": \"Blocking antibody experiments, solid-phase binding assay with purified protein, lipid raft fractionation, ERK1/2 activation assays, IL-8 gene expression assays, α5β1-negative BJAB cell controls\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct binding with purified protein confirmed in solid-phase assay, multiple blocking experiments, functional downstream signaling measured, independent receptor controls\",\n      \"pmids\": [\"17182621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CD40 ligation on endothelial cells induces expression of angiogenesis factors including VEGF, FGF-2, Flt-1, and Flt-4; in vivo injection of CD40L-expressing fibroblasts into human skin engrafted on SCID mice induces marked angiogenesis dependent on VEGF (blocked by anti-VEGF treatment), establishing CD40/CD40L as a VEGF-dependent proangiogenic pathway.\",\n      \"method\": \"Anti-CD40 antibody stimulation of cultured endothelial cells, SCID mouse human skin engraftment model, anti-VEGF blocking experiment, immunohistochemistry\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro and in vivo models with mechanistic blocking experiment (anti-VEGF), multiple angiogenic factors identified\",\n      \"pmids\": [\"12874247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"A20 overexpression in endothelial cells blocks CD40-induced NF-κB activation (upstream of IκBα degradation) and suppresses ICAM-1, VCAM-1, and E-selectin upregulation, but does not block CD40-induced tissue factor (TF) transcription, indicating CD40 induces TF through a non-NF-κB pathway; A20 also protects from CD40-mediated endothelial apoptosis.\",\n      \"method\": \"Transient transfection with CD40 and A20 expression constructs, NF-κB reporter assays, Western blot for IκBα, flow cytometry for adhesion molecules, colorimetric TF assay, RT-PCR, DNA content analysis for apoptosis\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — overexpression dissection with multiple molecular readouts distinguishing NF-κB-dependent vs. independent CD40 signaling branches, multiple orthogonal methods\",\n      \"pmids\": [\"12885753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CD40 ligation on pancreatic islet beta-cells activates ERK1/2 and NF-κB signaling pathways, inducing secretion of IL-6, IL-8, MCP-1, and MIP-1β (a chemokine not previously known to be produced by islets) and upregulation of ICAM-1; ERK and NF-κB inhibitors suppress cytokine/chemokine production, establishing these pathways as the mechanism of CD40-driven islet inflammation.\",\n      \"method\": \"CD40L stimulation of human and nonhuman primate islets and NIT-1 insulinoma cells, ELISA, quantitative RT-PCR, double-immunofluorescence, ERK1/2 and NF-κB pathway inhibitors\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway inhibition with multiple molecular readouts, validated at both protein and mRNA levels, human and primate islets plus cell line\",\n      \"pmids\": [\"16936191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CD40L-induced CD40L synthesis and MCP-1 release by endothelial cells is mediated through a redox-sensitive PI3K/Akt/NF-κB signaling axis; pharmacological inhibition of PI3K and p38 MAPK, and adenoviral inactivation of Akt and p38, blocked these effects; Akt overexpression augmented nuclear NF-κB translocation induced by CD40L, while Akt inactivation inhibited it.\",\n      \"method\": \"Pharmacological inhibitors (LY294002 for PI3K), adenoviral Akt and p38 overexpression/inactivation, confocal microscopy of NF-κB nuclear translocation, MCP-1 ELISA\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic (adenoviral) and pharmacological dissection of signaling pathway with NF-κB nuclear translocation as functional readout, multiple orthogonal methods\",\n      \"pmids\": [\"17459878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CD40 ligation on B cells stimulates antigen processing; co-culture of B cells with CD40L-expressing insect cells or anti-CD40 mAb augments activation of antigen-specific T cell hybridomas at lower antigen doses; this effect is on an intracellular processing step (not peptide presentation directly), is independent of B7, LFA-1, or CD23 upregulation, and does not require B cell proliferation.\",\n      \"method\": \"T cell hybridoma activation assays, co-culture with CD40L-expressing insect cells, anti-CD40 mAb, peptide presentation controls, flow cytometry for surface molecules\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional T cell activation assays with multiple controls ruling out alternative mechanisms, single lab\",\n      \"pmids\": [\"8566008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Neutrophils express CD40 (confirmed by RT-PCR and Western blot); platelet-neutrophil CD40-CD40L interaction enhances stimulation-induced platelet sCD40L release and augments neutrophil superoxide/ROS generation; this process is mediated via the PI3K/Akt pathway and forms a redox-controlled positive feedback loop where ROS further amplifies platelet sCD40L release.\",\n      \"method\": \"RT-PCR and Western blot for CD40 on neutrophils, ELISA for sCD40L, chemiluminescence and confocal microscopy for superoxide, flow cytometry for platelet-neutrophil conjugates, PI3K inhibitor (LY294002), N-acetylcysteine ROS scavenger, anti-CD40L blocking antibody\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods confirming CD40 expression and functional pathway with pharmacological dissection, single lab\",\n      \"pmids\": [\"18289643\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CD40 is a TNFR superfamily type I transmembrane receptor that lacks intrinsic kinase activity and signals by recruiting TRAF adaptor proteins (TRAF2, TRAF3, TRAF5, TRAF6, and c-IAP1) to its multimerized cytoplasmic domain upon CD40L (CD154) binding; downstream signaling activates NF-κB, MAPK pathways (ERK via Tpl2/TRAF6, JNK, p38), and PI3K/Akt, with distinct pathway branches controlling B cell proliferation, isotype switching, antigen processing, apoptosis resistance (via Bcl-xL), and inflammatory gene expression; NEDD4-mediated K63-ubiquitination of TRAF3 is required for AKT activation, Act1 negatively regulates the signaling complex, and AKNA coordinately transcribes both CD40 and CD40L; CD40 is expressed on B cells, dendritic cells, macrophages, endothelial cells, fibroblasts, neurons, eosinophils, and various other cell types where it mediates context-dependent functions including T cell priming through B7 upregulation, cDC1 survival via Bcl2l1, angiogenesis via VEGF induction, and inflammatory leukocyte recruitment.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CD40 is a type I transmembrane glycoprotein of the TNFR superfamily that functions as a co-stimulatory receptor coordinating adaptive and innate immune responses upon engagement by its ligand CD40L (CD154) [#2]. First identified as the B cell surface antigen Bp50 that augments proliferation of activated B cells [#0], CD40 lacks intrinsic kinase activity and signals through ligand-induced receptor multimerization: the trimerized cytoplasmic domain recruits a complex containing TRAF2, TRAF3, TRAF5, TRAF6, and c-IAP1 to drive NF-\\u03baB and downstream kinase activation [#6]. Distinct TRAF branches partition CD40 outputs\\u2014TRAF6 recruits Tpl2 to selectively activate ERK and IgE induction without affecting B cell proliferation [#7], TRAF5 mediates a separate subset of proliferative and surface-marker responses [#5], and NEDD4-driven K63-ubiquitination of TRAF3 is required for AKT activation and immunoglobulin class switching via AID [#11]. Signaling magnitude is restrained by the negative regulator Act1 [#8], while the transcription factor AKNA coordinately activates both CD40 and CD40L promoters [#10]. In the immune system, CD40 engagement on antigen-presenting cells upregulates B7.2 to license T cell priming [#4], enhances B cell antigen processing [#21], and in cDC1s induces Bcl-xL (Bcl2l1) to sustain dendritic cell survival during anti-tumor CD8 T cell priming [#14]. Beyond lymphocytes, CD40 is functional on endothelial cells\\u2014where it induces adhesion molecules, leukocyte recruitment, and VEGF-dependent angiogenesis [#3, #17]\\u2014as well as on macrophages where CD40-TRAF6 signaling drives atherosclerotic monocyte recruitment [#12], on neurons where it promotes survival via MAPK signaling [#15], and on islet beta-cells and neutrophils that mount inflammatory responses through ERK/NF-\\u03baB and PI3K/Akt pathways [#19, #22].\",\n  \"teleology\": [\n    {\n      \"year\": 1986,\n      \"claim\": \"Established CD40 (Bp50) as a functional B cell surface molecule delivering activation co-signals, answering whether this antigen had a regulatory role rather than being a passive marker.\",\n      \"evidence\": \"Monoclonal antibody stimulation and proliferation assays on purified resting versus activated B cells\",\n      \"pmids\": [\"3487090\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor identity and ligand unknown at this stage\", \"No molecular signaling mechanism defined\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Defined the immediate biochemical signaling response to CD40 engagement, showing it triggers tyrosine phosphorylation, phosphoinositide turnover, and serine/threonine kinase cascades.\",\n      \"evidence\": \"In vitro kinase assays, phosphoinositide turnover, and kinase inhibitor studies in B-lineage cells\",\n      \"pmids\": [\"1716631\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific kinases and adaptors not molecularly identified\", \"Link to transcriptional output not established\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Established CD40 as a TNFR-superfamily receptor for CD40L and linked CD40-IL-4/IL-13 co-stimulation to IgE isotype switching, defining its molecular identity and a functional output.\",\n      \"evidence\": \"Recombinant protein studies, gene mapping, and B cell stimulation/isotype switching assays (review of multiple studies)\",\n      \"pmids\": [\"7516669\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cytoplasmic signaling adaptors not yet identified\", \"Structural basis of receptor activation unresolved\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Extended CD40 function beyond lymphocytes by showing endothelial CD40 drives adhesion molecule expression and leukocyte adhesion, and demonstrated CD40 augments B cell antigen processing independent of proliferation.\",\n      \"evidence\": \"Soluble CD40L stimulation with blocking antibodies on endothelium; T cell hybridoma activation assays with CD40L-expressing cells\",\n      \"pmids\": [\"7540655\", \"8566008\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular signaling mediators in endothelium not defined\", \"Antigen-processing step affected by CD40 not molecularly identified\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Placed CD40 upstream of B7-CD28 co-stimulation in T cell priming and identified TRAF5 as a specific downstream mediator, beginning the dissection of branched CD40 outputs.\",\n      \"evidence\": \"CD40L-knockout mouse reconstitution with activating anti-CD40 plus anti-B7 blockade; TRAF5 knockout B cell phenotyping\",\n      \"pmids\": [\"8791591\", \"10449775\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TRAF5 selectively mediates a subset of signals while NF-\\u03baB/JNK remain intact unexplained\", \"Other TRAF contributions not yet resolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined the core activation mechanism\\u2014ligand-induced multimerization recruiting a TRAF2/3/5/6/c-IAP1 complex\\u2014and identified AKNA as a coordinate transcriptional regulator of CD40 and CD40L.\",\n      \"evidence\": \"Defined multimeric cytoplasmic-domain constructs with NF-\\u03baB reporters and complex co-isolation; promoter-binding and reporter assays for AKNA\",\n      \"pmids\": [\"11562359\", \"11268217\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structure of the receptor-TRAF complex not resolved\", \"How distinct TRAFs route to distinct outputs not fully defined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrated a non-immune role for CD40 in neuronal survival, showing CD40 signaling activates p44/42 MAPK and protects neurons, with CD40 loss causing progressive neuronal dysfunction.\",\n      \"evidence\": \"MAPK/JNK assays in neuronal cells plus CD40 knockout mouse brain phenotyping\",\n      \"pmids\": [\"11847112\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand source for neuronal CD40 in vivo unclear\", \"Adaptor usage in neurons not defined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Dissected endothelial CD40 signaling branches, establishing CD40-induced VEGF-dependent angiogenesis and an NF-\\u03baB-independent route to tissue factor, refining how CD40 outputs are pathway-partitioned.\",\n      \"evidence\": \"SCID mouse skin engraftment with anti-VEGF blockade; A20 overexpression dissecting NF-\\u03baB-dependent versus independent CD40 outputs\",\n      \"pmids\": [\"12874247\", \"12885753\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The non-NF-\\u03baB pathway driving tissue factor not identified\", \"Receptor-proximal events for angiogenic gene induction undefined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified Tpl2 as the kinase selectively coupling CD40-TRAF6 to ERK activation, dissociating ERK-dependent IgE induction from proliferation and providing a molecular basis for branched signaling.\",\n      \"evidence\": \"Tpl2 knockout mice, CD40/TRAF6/Tpl2 co-immunoprecipitation, and TRAF6 overexpression epistasis with Ig production assays\",\n      \"pmids\": [\"12881420\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TRAF6 selectively engages Tpl2 versus other effectors unresolved\", \"Contribution to other CD40 outputs not mapped\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Established Act1 as a negative regulator restraining CD40 signaling and showed CD40 signaling is largely silent in germinal center B cells, revealing how CD40 output is gated in space and intensity.\",\n      \"evidence\": \"Act1 and CD40-Act1 double knockout epistasis with signaling readouts; CD40 gene-expression signature and NF-\\u03baB localization in lymphoid tissue\",\n      \"pmids\": [\"15485634\", \"15331443\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism by which Act1 dampens the complex not fully defined\", \"What suppresses CD40 signaling within germinal centers unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Revealed CD40L can signal independently of CD40 by binding integrin \\u03b15\\u03b21, and extended CD40-driven inflammation to islet beta-cells via ERK/NF-\\u03baB chemokine induction.\",\n      \"evidence\": \"Solid-phase binding with purified \\u03b15\\u03b21 and downstream ERK/IL-8 assays; islet stimulation with ERK and NF-\\u03baB inhibitors\",\n      \"pmids\": [\"17182621\", \"16936191\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative in vivo contribution of CD40 versus \\u03b15\\u03b21 ligation unclear\", \"Receptor-proximal adaptors in islet beta-cells not defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined a redox-sensitive PI3K/Akt/NF-\\u03baB axis amplifying CD40L signaling in endothelium and a platelet-neutrophil CD40-CD40L feedback loop, linking CD40 to thrombo-inflammatory amplification.\",\n      \"evidence\": \"Adenoviral Akt/p38 manipulation and PI3K inhibitors with NF-\\u03baB translocation readouts; neutrophil/platelet ROS and conjugate assays with PI3K inhibitor and ROS scavenger\",\n      \"pmids\": [\"17459878\", \"18289643\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How PI3K/Akt couples to the receptor-TRAF complex in these cells not defined\", \"In vivo relevance of the redox feedback loop not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified NEDD4 as an E3 ligase that K63-ubiquitinates TRAF3 to enable CD40-driven AKT activation and class switching, connecting a specific ubiquitin event to a distinct signaling branch.\",\n      \"evidence\": \"Co-IP, K63-linkage ubiquitin analysis, NEDD4 loss-of-function, and AKT/AID/class-switch readouts\",\n      \"pmids\": [\"25072696\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural detail of NEDD4-CD40 interaction not resolved\", \"How TRAF3 ubiquitination is integrated with other branches unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Validated the CD40-TRAF6 protein-protein interface as a druggable node by showing small-molecule inhibitors block binding and reduce inflammation in vivo.\",\n      \"evidence\": \"In silico docking, in vitro interaction assays, and peritonitis/sepsis mouse models\",\n      \"pmids\": [\"25622654\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab validation of specificity\", \"Off-target effects not exhaustively excluded\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated selective CD40-TRAF6 blockade reduces atherosclerosis by limiting monocyte recruitment without impairing T cell or humoral immunity, establishing branch-selective therapeutic targeting.\",\n      \"evidence\": \"TRAF-STOP small molecules, Apoe-/- atherosclerosis models, transcriptional profiling, and NF-\\u03baB signaling assays\",\n      \"pmids\": [\"29406859\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term safety of chronic CD40-TRAF6 inhibition unknown\", \"Macrophage-intrinsic versus systemic contributions not fully separated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed CD40-induced Bcl-xL (Bcl2l1) sustains cDC1 survival to enable anti-tumor CD8 T cell priming, defining a survival output of CD40 in dendritic cells.\",\n      \"evidence\": \"cDC1-specific CD40 knockout, Bcl2l1 re-expression rescue, mitochondrial potential and caspase assays, and tumor rejection models\",\n      \"pmids\": [\"36271147\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor-proximal events driving Bcl2l1 induction in cDC1 not mapped\", \"Generalizability to other dendritic cell subsets unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How distinct TRAF/adaptor configurations and post-translational modifications are integrated at the multimerized receptor to select cell-type-specific outputs remains incompletely resolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure of the assembled CD40-TRAF signaling complex in the corpus\", \"Quantitative rules linking receptor occupancy to branch selection undefined\", \"Mechanism of context-dependent output across cell types not unified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [2, 6]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [16]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [6, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 2, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 7, 11]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 5, 14]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [12, 13]}\n    ],\n    \"complexes\": [\"CD40-TRAF signaling complex (TRAF2/TRAF3/TRAF5/TRAF6/c-IAP1)\"],\n    \"partners\": [\"CD40LG\", \"TRAF2\", \"TRAF3\", \"TRAF5\", \"TRAF6\", \"NEDD4\", \"ITGA5\", \"TRAF1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}